Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates. | | | | | Three Months Ended March 31, | | | | --- | --- | --- | --- | --- | --- | --- | | | | 2025 | | | 2024 | | | (in thousands, except ASP data) | | | | | | | | Revenue | $ | 15,498 | | $ | 14,415 | | | Gross margin | | 58.9 | % | | 59.6 | % | | Operating expenses | $ | 12,488 ...